Solly Chedid, MD

Articles by Solly Chedid, MD

Melissa BadamoMyelodysplastic Syndromes | November 20, 2024
In this roundtable segment, the panel discussed imetelstat for the treatment of lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 19, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss which patients with MDS should be treated with luspatercept.
Melissa BadamoMyelodysplastic Syndromes | November 18, 2024
Drs. Garcia-Manero, Koprivnikar, Chedid, and LeBlanc discuss dosing considerations for luspatercept for lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 15, 2024
The panel discussed the four COMMANDS trial abstracts on luspatercept for lower-risk MDS presented at EHA 2024.
Melissa BadamoMyelodysplastic Syndromes | November 14, 2024
In the next roundtable segment, the panel discusses risk stratifying patients with the IPSS-R and IPSS-M.
Melissa BadamoMyelodysplastic Syndromes | November 13, 2024
An expert panel discusses how to measure the MDS patient experience and whether it’s time for new endpoints in MDS.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | November 6, 2024
A roundtable discussion, moderated by Guillermo Garcia-Manero, MD, discussed the current state of MDS treatment.
Solly Chedid, MDMyelodysplastic Syndromes | October 24, 2024
COMMANDS is the first trial to perform a head-to-head comparison of luspatercept against an erythropoiesis-stimulating agent.